Post Date: June 10, 2021
Kurome Therapeutics, a spin-out company of Cincinnati Children’s that’s developing drugs to help combat cancer, has closed on $15 million in Series A financing.
The preclinical-stage company disclosed June 10, 2021, that it will use the funding to expand research and development.
The biology being investigated by Hyde Park-based Kurome was discovered by Daniel Starczynowski, PhD, who is principal investigator and co-leader of the Hematologic Malignancies Program at Cincinnati Children’s Cancer and Blood Diseases Institute.
The Starczynowski Laboratory is interested in the molecular, cellular, and genetic basis of hematologic malignancies, with a specific focus on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). MDS is a hematopoietic stem cell disorder resulting in abnormal blood cell production and a propensity to progress to AML.
Kurome treatments are initially focused on improving outcomes in poor prognosis patients with AML, but the company stated it will look to expand its focus across a range of hematopoietic cancers, including pre-leukemic conditions such as MDS as well as certain solid tumors where dysregulated IRAK1/4 signaling and inflammation may play a pathogenic role in tumorigenesis.
Launched in 2020, Kurome secured initial seed funding led by CincyTech based on research at Cincinnati Children’s in collaboration with the National Center for Advancing Translational Sciences, which is part of the National Institutes of Health.
For details, on the latest investment in Kurome, click here.
Read more about Starczynowski’s research.
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.